Pharmaceutical and life sciences companies are under intense pressure to introduce new products in an environment of escalating R&D costs, complex science, heightened regulatory scrutiny, and increased competition. The industry's traditional strategy of placing big bets on a few molecules, promoting them heavily and turning them into blockbusters worked well for shareholders for many years.